课题基金 / 基金详情

STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES

STRATEGIES TO ENHANCE ADOPTIVE TRANSFER OF T CELL CLONES
增强 T 细胞克隆过继转移的策略
批准号:
7958859
负责人:
STANLEY R. RIDDELL
金额:
$31.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2010-04-30

项目摘要

项目成果

STANLEY R. RIDDELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The adoptive transfer of antigen-specific CD8+ T cells is a promising treatment for human malignancies and infections. However, this approach is often limited by the poor persistence of transferred effector T cells (TE). Interleukin (IL)2 is frequently administered to support the survival of transferred T cells. High-dose IL2 can cause systemic toxicity, promotes the expansion of CD4+FoxP3+ regulatory T cells (Treg), which can inhibit antitumor immunity, and may promote activationinduced cell death of the transferred TE, if exposure is prolonged. IL15 is a novel cytokine that has a critical role in the maintenance of T-cell memory and may be an alternative to IL2 for supporting transferred T-cell survival. We first treated 5 macaques with IL15 (2.515 ¿g/kg s.c.) alone, either daily or every 3 days, and assessed toxicity and immunological effects. Daily IL15 increased the circulating NK and CD8+ T cells and expanded CD8+CD95+CCR7- effector memory (TEM) and CD95+CCR7+ central memory T cells (TCM). However, daily IL15 (515 ¿g/kg) accumulated in vivo, causing reversible toxicities. Intermittent IL15 treatment was safe, increased NK cells and CD8+ TEM or TCM, without boosting the CD4+ Treg. We then evaluated the ability of IL15 to support transferred CD8+ TE marked with CD19 in 2 macaques. As previously reported,1 TCM-derived CD8+ TE transferred without cytokines persisted in vivo at low levels of 0.20.8% of CD8+ cells. By contrast, T cells given with IL15 persisted at high levels (up to 10 % of CD8+ T cells) during and after treatment. The cells retained the ability to re-acquire a TCM phenotype and migrated to memory niches. Thus, IL15 can be safely administered and exerts a biologic effect on endogenous and transferred T cells. IL15 may be an alternative to IL2 or lymphodepletion to support the persistence of transferred T cells in human immunotherapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
  • 批准号:
    10601293
  • 项目类别:
  • 资助金额:
    $8.3万
  • 财政年份:
    2019
  • 负责人:
    STANLEY R. RIDDELL
  • 依托单位:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
  • 批准号:
    10436174
  • 项目类别:
  • 资助金额:
    $34.66万
  • 财政年份:
    2019
  • 负责人:
    STANLEY R. RIDDELL
  • 依托单位:
Project 2: Targeting Neoantigens for Lung Cancer Immunotherapy
  • 批准号:
    10700908
  • 项目类别:
  • 资助金额:
    $34.66万
  • 财政年份:
    2019
  • 负责人:
    STANLEY R. RIDDELL
  • 依托单位:
海外基金